Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice
Open Access
- 1 April 2005
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 64 (4) , 645-646
- https://doi.org/10.1136/ard.2004.028597
Abstract
We treated 168 patients with RA between 1 April 2000 and 1 October 2002, 82% female, with a median disease duration of 10 years (range 1–49). Inclusion criteria were 28 joint count Disease Activity Score (DAS28) of >3.5 and failure of two disease modifying antirheumatic drugs, including methotrexate. Patients with heart failure or with a malignancy 5 years before screening were excluded. After the alert about tuberculosis,6 patients starting with infliximab treatment were screened for that disease.Keywords
This publication has 8 references indexed in Scilit:
- Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapyRheumatology, 2003
- Predictors of infection in rheumatoid arthritisArthritis & Rheumatism, 2002
- Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based studyArthritis & Rheumatism, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatmentAnnals of the Rheumatic Diseases, 1999
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994